Overview
XGN market data
Price History
XGN price chart · 1M
- O
- 7.55
- H
- 7.75
- L
- 7.42
- C
- 7.66
- Vol
- 12,248.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $7.55
- Previous Close
- $7.60
- Day High
- $7.75
- Day Low
- $7.42
- 52 Week High
- $7.97
- 52 Week Low
- $2.59
- 7 Day Return
- +3.23%
- 30 Day Return
- +74.49%
- 90 Day Return
- +50.34%
- 1 Year Return
- +132.83%
- Daily Notional Volume
- $93.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.93 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.16 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -26.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.59 – $12.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $159.2M · P/B 7.78 · P/S 2.24.
Company News
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10Benzinga · Aug 5, 2026, 7:36 PM
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12Benzinga · Aug 5, 2026, 4:50 PM
BTIG Maintains Buy on Exagen, Raises Price Target to $9Benzinga · Aug 5, 2026, 12:08 PM
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.Benzinga · Aug 4, 2026, 2:21 PM
8-K filing — EXAGEN INC. (XGN)SEC EDGAR · Aug 4, 2026, 12:02 PM
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M EstBenzinga · Aug 4, 2026, 12:01 PM
Exagen Q2 EPS $(0.13) Beats $(0.19) Estimate, Sales $19.941M Beat $17.817M EstimateBenzinga · Aug 4, 2026, 12:01 PM
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests AloneBenzinga · Jun 1, 2026, 1:03 PM